Leuprorelin depot - Foresee/ScinoPharma

Drug Profile

Leuprorelin depot - Foresee/ScinoPharma

Alternative Names: FP-001; leuprolide controlled-release - Foresee/ScinoPharma; Leuprolide Mesylate - Foresee/ScinoPharma

Latest Information Update: 28 Mar 2016

Price : $50

At a glance

  • Originator Foresee Pharmaceuticals - ScinoPharm (JV)
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Feb 2016 Foresee Pharmaceuticals initiates a safety extension phase III trial for Prostate cancer (Late-stage disease) in USA (SC) (NCT02712320)
  • 07 Dec 2015 Phase-III clinical trials in Prostate cancer (Late-stage disease) in Austria, Czech Republic, Germany, Slovakia, Lithuania and Poland (SC) (EudraCT2013-001790-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top